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Abstract—We have studied the interaction of the aminoglycoside drug, paromomycin, with a 171-mer from the packaging region of
HIV-1 (c-RNA), using quantitative footprinting and circular dichroism spectroscopy. The footprinting autoradiographic data were
obtained by cutting end-labeled RNA with RNase I or RNase T1 in the presence of varying paromomycin concentrations. Scan-
ning the autoradiograms produced footprinting plots showing cleavage intensities for specific sites on the c-RNA as functions of
drug concentration. Footprinting plots showing binding were analyzed using a two-state model to give apparent binding constants
for specific sites of the c-RNA. These plots show that the highest-affinity paromomycin binding site involves nucleotides near
bulges in the main stem and SL-1, and other nucleotides in SL-4 of the c-RNA. RNase I gives an apparent value of K for this drug
site of 1.7105 M1 while RNase T1 reports a value of K of 8104 M1 (10 mM Tris HCl, pH 7). Footprinting shows that
loading the highest affinity site with paromomycin causes structural changes in the single-stranded linker regions, between the stem-
loops and main stem and the loops of SL-1 and SL-3. Drug-induced structural changes also affect the intensity of the 208 nm band
in the circular dichroism spectrum of the c-RNA. Fitting the changes in CD band intensity to a two-state model yielded a binding
constant for the highest-affinity drug site of 6106 M1. Thus, the binding constants from footprinting are lower than those
obtained for the highest-affinity site from the circular dichroism spectrum, and lower than those earlier obtained using absorption
spectroscopy (Sullivan, J. M.; Goodisman, J.; Dabrowiak, J. C., Bioorg. Med. Chem. Lett. 2002, 12, 615). The discrepancy may be
due to competitive binding between drug and cleavage agent in the footprinting experiments, but other explanations are discussed.
In addition to revealing sites of binding and regions of drug-induced structural change, footprinting showed that the loop regions of
SL-1, SL-3 and SL-4 are exposed in the RNA, whereas the linker region between SL-1 and SL-2 is ‘buried’ and not accessible to
cutting by RNase I or RNase T1.
# 2002 Elsevier Science Ltd. All rights reserved.
Introduction
The aminoglycosides are drugs that exhibit antibacterial
effects by binding to the A site of ribosomal RNA.1,2
Puglisi and co-workers35 used NMR to show that the
aminoglycoside paromomycin (Fig. 1) binds to a bulged
region of A-site RNA. Ring I of the drug occupies a
binding pocket created by a non-canonical A.A base
pair, while the amino groups on the 2-deoxysteptamine
ring (ring II) of paromomycin are involved in hydrogen
bonds with heterocyclic bases that form the binding
pocket. A crystal structure of paromomycin bound to a
novel RNA construct containing two A-sites has also
recently been published. The structure shows par-
omomycin bound in an enlarged deep groove created by
two bulging and one unpaired adenines with the drug
extensively hydrogen bonded through water to RNA.6
Although NMR710 and various other techniques1118
have been used to study aminoglycoside–RNA inter-
actions, a clear picture of the factors that control bind-
ing specificity has not yet emerged. In general, the drugs
prefer to bind to bulged or other non-Watson–Crick
secondary elements of RNA. This is mainly because the
drugs are too large to fit into the grooves of regular
A-form RNA structures. The aminoglycosides have a
number of protonated amine groups, the spatial orien-
tation of which can be easily changed. Since these
groups are often involved in hydrogen bond and/or
electrostatic interactions with sites on RNA, the drugs
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can adapt to a variety of different binding pockets on
RNA.
In an effort to explore the structural features of the drug
that affect the affinity and specificity, Tor and co-work-
ers chemically modified a number of aminoglycosides by
attaching intercalators and reporting groups19,20 and by
forming drug dimers.21 These analogues selectively
inhibit the catalytic effects of ribozymes, and they are
able to prevent proteins from binding to their interac-
tion sequences on RNA. Tor, Goodman and co-work-
ers22 also synthesized the guanidinum analogues of
tobramycin and neomycin B. These analogues were
found to be about 100 times more effective than the
parent aminoglycosides in inhibiting replication of the
HIV virus in HeLa cells.
Although RNA is an attractive target for drugs,23 rela-
tively little is known about the way in which it can bind
small ligands. Potential RNA targets are often large
molecules that can fold into complex structures having
many binding pockets for drugs. Measuring the affi-
nities of drugs for various sites and identifying the
structural features of RNA that form sites is critically
important for designing agents that can selectively bind to
one RNA in the presence of a number of competing
RNAs. In an earlier report,24 we outlined the theory and
experimental protocols needed to obtain binding constants
from drug–RNA footprinting data, using as an example
the aminoglycoside drug paromomycin, and c-RNA from
the packaging region of HIV-1 (LAI), (Fig. 1). Since this
segment of RNA controls a number of important steps in
the life cycle of the virus,25 modifying its function with
drugs may be an effective way of blocking the spread of the
virus that causes AIDS. We have found that the absorp-
tion spectrum of c-RNA is sensitive to the presence of
paromomycin and other aminoglycoside drugs.26 By fit-
ting the absorbance changes at 260 nm to a two-state
model and assuming that, at low drug concentrations, a
single drug binds to the highest affinity binding site, the
binding constant was found to be 1.8106 M1.
In this report, we quantitatively analyze RNase I and
RNase T1 footprinting data for paromomycin interact-
ing with c-RNA obtaining apparent binding constants
from the spot intensities appearing on the footprinting
autoradiogram. The footprinting data are compared
with the paromomycin-induced changes in the circular
dichroism spectrum of c-RNA.
Results and Analysis
Theory
In the quantitative footprinting experiment involving
drug binding to RNA24 or DNA27,28 one obtains foot-
printing plots showing how the intensity of a given band
on the autoradiogram, corresponding to the rate of
cleavage at a particular nucleotide position, changes
with drug concentration. The rate of cleavage, Ri, is
equal to the product of the concentration of the nucleo-
tide, [Si], the concentration of the cutting agent at the
nucleotide position, [Ci], and the rate constant associated
with cleavage (in this case, hydrolysis) at the site, ki.
Ri ¼ ki Si½  Ci½  ð1Þ
For RNase I, the rate constant ki, is relatively large for
single-stranded RNA, particularly at A, while, for
RNase T1, ki is large for sites with unpaired G.
29
The concentration of a particular nucleotide position
that is not covered by drug, [Si], is related to the total
concentration of nucleotides at that position, [Si]T, by
the drug binding equilibrium:
Ki ¼
Si½ T Si½ 
Si½  D½ 
ð2Þ
Here, Ki is the equilibrium constant for paromomycin
binding at a specific nucleotide i, [D] is the concentration
Figure 1. (a) Model of -RNA from the packaging region of HIV-1
(LAI) with a summary of binding/enhancement information for par-
omomycin. The RNA consists of the ‘main stem’, positions 213–238
and 361–388; SL-1, which contains the Dimer Initiation Site; SL-2,
having the 50 splice donor site; SL-3, and SL-4, the latter containing
the start codon (AUG) for the gag gene. Nucleotides involved in
binding and enhancement (structural changes) for RNase I are shown
as filled circles and triangles, respectively. Nucleotides involved in
binding and enhancement (structural changes) for RNase T1 are shown
as open circles and triangles, respectively. (b) Structure of paromomycin.
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of free drug, and [Si]T[Si] is the concentration of sites i
with drug bound. Since there is one site i on each oli-
gomer, [Si]T is equal to the oligomer concentration ST.
The free-drug concentration is the total drug con-
centration minus the concentration of drug bound at all
sites on the oligomer. Since [C]i is equal to the total
concentration of cleavage agent minus the concentra-
tion of cleavage agent actually involved in the cleavage
process, [C]i is expected to be the same for all sites.
Writing it as [C], we have
Ri ¼ ki C½ 
ST
1 þ Ki D½ 
ð3Þ
The intensity of the spot on the gel corresponding to
cleavage at site i, Ii, is proportional to Ri. Eq. 3 explains
footprinting plots associated with sites at which binding
is taking place and spot intensities decrease with added
drug, called type 1 plots. If the free-drug concentration
were known, one could obtain site-specific binding con-
stants Ki by fitting plots of spot intensity versus free-
drug concentration to the Langmuir form,
Ii=ai(1+Ki[D])
1. However, there are two potential
problems with extracting binding constants from foot-
printing data.
One is that, in the footprinting experiment, usually only
the total drug concentration, DT, is known. Since [D] is
a monotonic function of DT, it is possible to use the






Larger values of bi can be shown to correspond to lar-
ger values of Ki. If it is known that only a single
binding event is taking place (as for drug concentra-
tions for which only the primary site is loading),
[Si]T[Si] is equal to the concentration of bound
drug, which is DT[D]. This two-state model makes
eq 2 become
Ki ¼
ST  Si½ 
½Si DT  ST þ Si½ ð Þ
ð5Þ
which is a quadratic equation to be solved for [S]i, given
Ki, DT and ST=[Si]T. Then one can substitute [Si] for
each DT into eq 1 and find the values of Ki and ki[C]
which give the best fit to the footprinting plot. For sec-
ondary sites, [D] is smaller than DTST+Si, and the
model underestimates Ki. Another problem with bind-
ing constants from footprinting data is related to the
cutting agent. If it competes with the drug for binding to
a site, the drug binding constant from footprinting will
be too low. This is not a problem if the cutting agent is
non-specific (binds and cuts at many sites), and if the
ratio of polymer sites covered by drug to those that are
free is small. This situation is found for many quantita-
tive drug-DNA footprinting experiments involving the
non-specific enzyme, DNase I, and relatively long frag-
ments (200 bp) of DNA.27,28,30 However, if the cut-
ting agent can bind at only a few sites, and its binding
constant is comparable to that of the drug, the drug and
the cutting agent effectively compete for the same site,
and footprinting data will give a value of K that is lower
than the true value.31
A drug-induced increase in cutting at a site, called an
‘enhancement’, can also occur in footprinting experi-
ments. If all of the cutting sites are not covered with the
cutting agent, drug binding to the polymer will displace
the cutting agent to other sites, which increases Ri in
eq 1 by increasing [Ci]. However, Ri can also be
increased without displacement if drug causes a struc-
tural change in the polymer, changing ki in eq 1. For
single-stranded RNAs, which can readily adopt a vari-
ety of secondary structures, enhancements in drug-
RNA footprinting experiments are most likely to occur
by the latter mechanism.
Footprinting data
The conditions of the RNase I and RNase T1 foot-
printing experiments, given in an earlier report,24 are
briefly summarized in the Experimental of this work.
The footprinting autoradiograms, Figures 2 and 3, were
scanned and intensities of bands, each corresponding to
cleavage of RNA at different sites on c-RNA, were
measured. Footprinting plots were of several types: type
1, band (cutting) intensity decreases with drug con-
centration; type 2, intensity increases with drug con-
centration up to some maximum and then decreases;
type 3, intensity increases with drug concentration; type
4, intensity hardly changes with drug concentration.
When compared to RNase I, RNase T1 had fewer cut-
ting sites on the c-RNA. Most of the plots for RNase
T1 were type 1, but, in the type 2 plots, decreases
occurred at higher drug concentration than for RNase
1. Selected footprinting plots from the RNase I and
RNase T1 experiments are shown in Figures 4 and 5,
respectively.
RNase I. Representative footprinting plots for RNase I
cleaving c-RNA in the presence of paromomycin are
shown in Figure 4. Apparent binding constants for
paromomycin, derived from footprinting data, are given
in Table 1. The binding constants obtained with RNase
I fall into two groups that differ in the apparent value of
Ki by about a factor of 2.
Type 1 plots were found for sites A235 and A239, and
for site A276, giving values of Ki of 1.6105 M1 and
1.7105 M1, respectively. (The values of Ki were
determined to minimize R, the sum of the squared
deviations between observed and calculated spot inten-
sities on all three footprinting plots.) These nucleotides
M. P. McPike et al. / Bioorg. Med. Chem. 10 (2002) 3663–3672 3665
are located at or near bulges in SL-1 and the main stem.
This enzyme also detects drug binding at C267, A268,
and A269, in SL-1, and at A286, in SL-2, with values of
Ki of 8104 and 6104 M1, respectively. These
nucleotides, at which cutting is weak, are located in
regions of the c-RNA that are predicted to have duplex
character (see Fig. 1).
The footprinting plots for 267, 268 and 269, which
reflect the same binding event, were analyzed together
using a single value of Ki (but a different value of the
parameter ki[C] for each—see eq 3). The uncertainties in
the Ki were estimated at almost 50%, so they could be
identical; both are significantly different from K235. The
error in K235 was estimated by fixing K235 at a value
different from the best value and minimizing R, the sum
of the squared deviations, with respect to the parameter
k235[C]. We found the change in Ki which increased the
minimum R by 10% over the best value. The result was
K235=(1.60.5)105 M1.
Most of the footprinting plots observed for RNase I are
type 2, for which cutting increases to a maximum fol-
lowed by a decrease. These mainly occur in regions of
the c-RNA that are predicted to be single-stranded,
that is, 241–245 (between the main stem and SL-1), 300–
311 (between SL-2 and SL-3), 326- 336 (between SL-3
and SL-4), and at A356, A359, A360 (between SL-4 and
the main stem).
RNase T1. Typical footprinting plots for RNase T1 are
shown in Fig. 5. The type 1 footprinting plots for
RNase T1 return apparent values of Ki for par-
omomycin that are in general lower than those obtained
with RNase I, Table 1. The drug site with highest affi-
nity, Ki 7104 M1, is at positions G338, G339,
G340, G344, and G346, in the start codon of the gag
gene and in SL-4. This enzyme also detects a par-
omomycin binding site at positions G328, G329, G331,
G333, and G335 with an apparent value of Ki 7104
M1. RNase T1 also finds two ‘low K’ paromomycin
binding events at G251 and G254, in the stem of SL-1,
Figure 3. Footprinting autoradiogram of cleavage of -RNA using
RNase T1 in the presence of paromomycin. Lanes 1 and 2, RNA
alone; lane 3, cleavage of RNA by hydroxide; lane 4, RNase A clea-
vage ladder. The lane number and concentration of paromomycin
(micromolar), respectively, are 5, 0; 6, 5; 7, 10; 8, 15; 9, 20; 10, 25; 11,
30; 12, 35; 13, 40; 14, 45; 15, 50 (not scanned); 16, 55; 17, 60.
Figure 2. Footprinting autoradiogram of cleavage of -RNA using
RNase I in the presence of paromomycin. Lanes 1 and 2, RNA alone;
lane 3, hydroxide ion cleavage ladder; lane 4, RNase T1 ladder (G);
lane 5, RNase A ladder (C, U). The lane number and concentration in
micro molar of paromomycin respectively are: 6, 0; 7, 2.5; 8, 5; 9, 7.5;
10, 10; 11, 12.5; 12, 15; 13, 17.5; 14, 20; 15, 25; 16, 30; 17, 35; 18, 40;
19, 45; 20, 50. The sequence of the RNA is shown in Fig. 1. The
footprinting experiments were carried out in the buffer, 10 mM Tris–
HCl (pH 7).
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and at the pentameric guanine sequence, G363, G364,
G365, G366, and G367, in the main stem. These par-
omomycin binding sites have values of Ki of 2.8104
M1 and 2.6104 M1, respectively. Type 3 plots for
this enzyme, for which cutting increases with drug con-
centration, are in the loop regions of SL-1 (G257, G259,
and G261), and SL-3 (G317, G318 and G320). Spot
intensities for the loop region of SL-2 were obscured by
a strong band in the control lane of the gel.
Circular dichroism titrations
Circular dichroism (CD) spectra in the presence and
absence of paromomycin are shown in Figure 6. The
CD spectrum of the c-RNA resembles that for A-form
RNA,32,33 with bands at 266, 240 and 208 nm, having
values of e (M1 cm1 nucleotide1) of +3.9, 0.8,
and 3.6, respectively. With added drug, the negative
band at 208 nm intensifies, and its position shifts
slightly, to 210 nm. The maximum intensity is attained
at 20 mM paromomycin concentration. At higher
paromomycin concentrations, this band decreases in
intensity (becomes less negative) with added drug (Fig.
6, inset). A similar but weaker effect occurs for the low-
intensity band at 240 nm.
In order to determine the number of binding events and
to calculate apparent paromomycin binding constants
for the events, we smoothed the data of Figure 6 (using
a Fourier transform algorithm) and obtained, from the
smoothed data, e as a function of drug concentration.
Some these results are plotted in Figure 7. At the higher
wave lengths, the changes in e were too small to be
analyzed. In each plot of Figure 7, e decreases with
total drug concentration, DT, for small DT and levels off
as DT approaches 20 mM For DT exceeding 20 mM, e
increases again, possibly because another binding event
that alters RNA structure occurs, or possibly because
Table 1. Binding constants (in M1) determined from footprinting
studies
Site numbers With RNase I With RNase T1
A235, A239 1.6105
G251, G254 2.8104
C267, A268, A269 8104
A276 1.7105
A286 6104
G328, G329, G331, G333, G335 7104
G338, G339, G340 6104
G344, G346 7104
G363, G364, G365, G366, G367 2.6104
Figure 4. Footprinting plots for the RNase I experiments (optical density versus total drug concentration in mM) obtained for paromomycin interacting
with -RNA. The site numbers correspond to the sequence shown in Fig. 1. Small negative intensities arise from subtraction of control-lane intensities.
Figure 5. Footprinting plots for the RNase T1 experiments (optical
density versus total drug concentration) obtained for paromomycin
interacting with -RNA. The site numbers correspond to the sequence
shown in Figure 1.
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RNA is precipitating from solution. Because of the lat-
ter possibility, the event responsible for e becoming
less negative at DT>20 mM was not analyzed. It can
also be seen that e decreases much faster with DT for
concentrations below about 1.5 mM than it does for
higher concentrations. This suggests that there are at
least two CD-detectable binding events for DT <20 mM.
Therefore, we analyzed the data two ways. We first
obtained a single binding constant from all the data for
DT<20 mM, with the understanding that this is an
average or effective binding constant for the binding
events taking place in this concentration range. Second,
we analyzed the five data points for DT<1.5 mM to
obtain an approximate value for the binding constant
associated with the strongest binding event.
In each analysis, it was assumed that the change in e
with drug concentration was due to a single drug-bind-
ing event. Suppose that, at some wave length, e=a for
the RNA with no drug bound and e=b for the RNA
with drug bound. If the binding constant is K,
" ¼ 
1
1 þ K D½ 
þ 
K D½ 








Let RT be the total RNA concentration, [R] the con-
centration of RNA with no drug bound, and [RD] the
concentration of RNA with drug bound
(RT=[R]+[RD]). Since
RD½ 
R½  D½ 
¼
RD½ 
RT  RD½ ð Þ DT RD½ ð Þ
ð7Þ
is a quadratic equation for [RD], one can obtain, using
eqs 6 and 7, e as a function of RT, DT, a,b and K. RT
is known, and one seeks the values of a,b and K which
give the best fit to the experimental values of e as a
function of DT.
Some of the fits to the data for DT <20 mM are shown
in Figure 7. They correspond to K=7.3104 M1,
1.6105 M1, and 1.7105 M1. When all seven data
sets shown in Figure 6 are analyzed in this way, we
obtain K=(1.280.35)105 M1 (averageaverage
deviation from the mean). Performing the same analysis
on the data for DT<1.5 mM (e for the five lowest
values of DT) for wave lengths of 205, 210, 215, 220, and
225 nm (see Fig. 7), we obtain K=(66)106 M1
(averageaverage deviation from the mean). The large
scatter is because most of the change in e takes place
in the first three points. We may also estimate the
uncertainty in K by seeking the changes in K (the same
K is used for all wave lengths) which increase the sum of
the squared deviations of calculated from experimental
e over the best fit by 10%. This gives ln K=15.61.1
(K is uncertain within a factor of 3).
Discussion
Structure of the  -RNA
The secondary structure of the packaging region of HIV
was previously characterized using chemical and enzy-
matic cleavage agents and by application of folding
programs to the sequence.3437 While there is some dis-
agreement about the structure of certain duplex regions,
most of the evidence suggests that the packaging region
has four stem-loops, designated SL-1 through SL-4 in
Figure 1. Clever et al.35 showed that while SL-4 seems
to be present, it contains a relatively high percentage of
G.U base pairs and it is probably less stable than the
other stem-loops. In addition to these four stem-loops,
the c-RNA used in this study has sequences that extend
in the 30 direction into the coding region of the gag gene,
and, in the 50 direction, into the primer binding site. A
Figure 7. Observed circular dichroism, e (M1 cm1 nucleotide1),
at various wave lengths, as a function of the logarithm of the drug
concentration. For wave lengths above 240 nm, the changes in e with
[paromomycin] are too small to be analyzed. For the first three wave
lengths, the results of fitting to a two-state model (single drug binding
event) are shown as dashed lines.
Figure 6. CD spectra of -RNA, e (M1 cm1 nucleotide1), for
various paromomycin concentrations. For clarity, spectra for [par-
omomycin] <20 mM are shown in the main plot, and spectra for
[paromomycin] >20 mM are shown in the inset. As seen in Figure 7,
the intensity of the negative band increases with drug concentration
below 20 mM and decreases with drug concentration above 20 mM.
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check of the sequence of the c-RNA used in this study
revealed that T7 RNA polymerase failed to transcribe a
pentameric sequence in the template DNA and that the
pentamer, AAAUU (303–307), in the coding sequence
of HIV-1 (LAI), is missing in the c-RNA. The predic-
tion of the secondary structure of the c-RNA was done
using Mfold v3.0 algorithm38 offered at http://bioinfo.-
math.rpi.edu. Folding was done at 37 C with 1 M
NaCl, specifying that the regions between SL 3 and SL
4, and SL 4 and the main stem, be single stranded (the
enzymes cut in these regions). Since the footprinting and
CD studies were done at a different temperature (21 C)
and ionic strength (10 mM Tris–HCl, pH 7) from those
employed in the folding program Mfold, the complete
secondary structure is unknown. Thus, pending the
outcome of additional work, the structure shown in
Figure 1 is only intended to be a ‘working model’ on
which the binding/structural information for par-
omomycin is summarized. Mfold38 predicts that the
sequences on the 30 side of SL-4 and to the 50 side of SL-
1 form a ‘main stem’ (Fig. 1). This is consistent with the
general lack of RNase I cutting in this region (RNase I
prefers to cut at single stranded regions) (Fig. 2). Nei-
ther enzyme cuts in the linker region between SL-1 and
SL-2. While this region was cut in an RNA fragment
studied by Clever et al.,35 it appears to be hidden in the
c-RNA used in this study. The loop regions of SL-1,
SL-3, and SL-4 are cut only by RNase T1. When drug
binds, sites in the loops of SL-1 and SL-3 exhibit clea-
vage enhancements, while those in SL-4 give type 1
footprinting plots, indicative of drug binding (Figs 2–5).
The packaging region of HIV can form a dimer in which
the palindromic sequence present in the loop of SL-1 is
base-paired with its complement in a second copy of the
genomic-length RNA. However, the fact that sites in
this loop are cleaved strongly by RNase T1 indicates
that the c-RNA is monomeric.
Binding of paromomycin to the  -RNA
In this work we study the binding of the aminoglycoside
drug, paromomycin, to a complex RNA molecule from
the packaging region of HIV-1 (LAI). The footprinting
data show how drug affects cutting at specific sites. For
some sites, the footprinting plots (spot intensity versus
drug concentration) were type 1, indicating drug bind-
ing which blocks cleavage. Apparent binding constants
for paromomycin at such sites were obtained by ana-
lyzing the footprinting plots using a two-state model,
which assumes that one drug molecule was involved in
the binding event. This gave values of K that were sig-
nificantly lower than those obtained by analyzing, using
the two-state model, the changes in the absorption26
and CD spectra at low drug concentrations.
There could be several reasons why the values of K from
footprinting disagree with those from the optical meth-
ods. (1) It is possible that the highest affinity binding site
(detected by optical methods) was not measured in the
footprinting experiments. Using RNase I and RNase
T1, cleavage intensities high enough to be measured
were obtained for 40% of the nucleotides of the
RNA. The drug would be expected to cover 5
nucleotides and, although the enzyme may be blocked
from cutting at several more sites, there are regions for
which no cutting information is available. (2) The dis-
crepancies between the values of Ki between footprint-
ing and optical methods may be due to competitive
binding in the former. If the enzyme competes with the
drug for binding at the same sites, the values of Ki
derived from footprinting intensities will be too low,
although relative values will be correct. Since effective
competition between drug and cutting agent depends in
a complex way on the concentrations of drug and cut-
ting agent, their binding constants for RNA, and the
number of cutting sites for which both compete, it is
difficult to prove that competition is the reason for the
discrepancy. Competitive binding does explain the appar-
ent difference between Ki values obtained from the two
enzymes. However, the binding constant of one of the
enzymes, RNase T1,39 is 3104 M1, which is about 2
orders of magnitude lower than Ki for paromomycin
binding to the c-RNA determined by optical methods26
and paromomycin binding to other RNAs.14 (3) It may be
that the binding which produces the distortions detected
by optical methods is different in character from that
detected by footprinting. For the former, it may suffice
for drug to be near the RNA molecule, without actually
binding to a specific site. For bound drug to induce a
decrease in cleavage, the drug molecule must block the
approach of the cleavage agent to the site.
Inspection of the autoradiograms and the footprinting
plots, Figures 2–5 and Table 1, reveals that the highest-
affinity sites detected by RNase I are at positions A235,
A239, and A276 while the sites of highest affinity detec-
ted by RNase T1 are guanine residues in SL-4: 338–340,
344, and 346. Whether the various nucleotides come
together to form a binding pocket (s) for paromomycin
is difficult to determine. However, it is conceivable that
they could all be responding to the same drug binding
event, in which case the values of Ki reported for the site
are not the same for the two enzymes (Table 1). This
would imply that drug and enzyme are in competition
for the site, and that RNase T1 binds more strongly to
RNA than RNase I (Table 1). The more likely possibi-
lity is that these nucleotides form more than one binding
pocket for paromomycin and that the nucleotides affec-
ted are part of more than one site.
The RNase I footprinting results clearly show that,
when A235, A239, and A276 bind drug, many
enhancements (type 2 plots) occur in the single-stranded
linker regions of the c-RNA. Although RNase T1
shows fewer enhancements (type 3 plots), they occur in
the loop regions of SL-1 and SL-3, where RNase I does
not cut. Since CD and absorption show that the orien-
tation of bases and the amount of base stacking change
when drug binds to the highest affinity sites, the
enhancements observed in the footprinting experiments
appear to be structural in origin.
Interestingly, RNase I and RNase T1 report different
behavior for the homopurine tract at positions 325–336
(sequence GAAGGAGAGAGA). RNase I, which cuts
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at the adenines, gives type 2 footprinting plots, but
RNase T1 gives type 1 plots at the guanines in the
sequence. A possible explanation for this is that the
region is undergoing a structural change induced by
drug binding at another site j, and that this change
facilitates cutting by RNase I but hinders cutting by
RNase T1. Although RNase I does not cut in SL-4
itself, the footprinting plots look more like binding plots
as one approaches the 30 end of the homopurine tract,
that is, the intensity of the maximum is decreased and it
is shifted to lower drug concentration. This is consistent
with the nucleotides in SL-4 being part of a binding
pocket for the drug.
As shown in Table 1, both enzymes report secondary
binding sites on the c-RNA. The drug site seen by
RNase T1 at G251 and G254 in the stem of SL-1 may
be the same drug site seen by RNase I at C267, A268,
and A269 on the other ‘side’ of the stem. If this is the
case, the difference in the values of Ki by about a factor
of three may be explained by competitive binding, with
RNase T1 being the stronger binder of the two enzymes
toward RNA. RNase T1 also detects a weaker site at an
oligo-guanine tract at 363–367, which is located in the
main stem of the RNA.
From the CD changes (Figs 6 and 7) it is clear that
paromomycin changes the structure of the c-RNA.
Since the intensity of the 208 nm band is affected when
the linker regions and the loops of SL-1 and SL-3 are
undergoing footprinting enhancements, this CD band is
affected by the relative orientation of bases in these
regions. As discussed above, CD detects a high-affinity
binding event for drug concentrations below 1.5 mM,
and another event in the range 1.5–20 mM. Interpreting
both according to the two-state model, we find effective
binding constants of (66)106 M1 and
(1.280.35)105 M1. It is possible that the change in
CD in each range is due to multiple drug-binding events
with the same or similar values of Ki, each of which
changes the CD in a different way. This situation would
require analysis using a model more complex than that
employed. Many of the footprinting plots obtained with
RNase I show enhancement followed by a decrease in
cutting at higher drug concentration, type 2 plots. The
increasing parts of these plots can be explained by a
drug-induced structural change while the decreasing
portions could be due to either a second structural
change or drug binding. Determining which situation is
the case will require additional study.
The packaging region of HIV initiates the formation of
the genomic length RNA dimer found in the virion of
the virus.25 This is believed to occur through SL-1,
which contains the palindromic sequence GCGCGC at
positions 257–262 of the c-RNA.40,41 The RNase T1
footprinting studies clearly show that this loop is free,
and that it undergoes a structural change in the presence
of paromomycin. To what extent paromomycin may
affect the monomer-dimer equilibrium involving the
c-RNA remains to be seen. However, the bulge region
of SL-1, adjacent to A276 and part of a binding pocket
for the drug, is thought to regulate the inter-conversion
between the ‘kissing’ and extended duplex forms of the
HIV RNA dimer.42 The packaging region is also bound
by the nucleocapsid protein NCp7 in the virion of
HIV.25 Since drug binding could displace protein from
RNA, paromomycin and its analogues could affect the
organization and compaction of RNA in the virus par-
ticle which could in turn influence viral infectivity.
Conclusions
In this work, we use quantitative footprinting methods
to identify binding sites for the aminoglycoside drug
paromomycin on a segment of RNA from the packa-
ging region of HIV-1 (LAI). The footprinting auto-
radiographic data were used to construct plots (called
footprinting plots) showing how cutting at various sites
changes with drug concentration. Plots showing decrea-
ses in spot intensity with drug concentration are referred
to as type 1, or binding plots. These were analyzed using
a two-state binding model, assuming a binding stoi-
chiometry of 1:1, to give apparent binding constants for
the drug. The values of K derived using this approach
were lower than the values of K obtained from changes
in the CD spectrum of the RNA at low drug con-
centration. The highest affinity paromomycin site
detected by RNase I involves nucleotides in SL-1 and
the main stem and it may be part of the same site
detected by RNase T1 in SL-4. Footprinting and CD
show that drug binding to this site causes the linker
regions and loops of SL-1 and SL-3 to change con-
formation. These studies show that quantitative foot-
printing in conjunction with circular dichroism can
provide information concerning drug binding sites and
regions of structural change on a segment of RNA from
the packaging region of HIV.
Experimental
Footprinting
The synthesis, purification and 50-end labeling (32P) of
the 171-mer c-RNA were given earlier.25 Preliminary
experiments were necessary to determine the amounts of
RNase I and RNase T1 and the cutting time required
for ‘single hit’ conditions, such that less than 20% of
the full length RNA is cut during the reaction. Enzymes
were chosen over a number of possible chemical clea-
vage agents because the extent of digest with an enzyme
is easily controlled (required for quantitative studies)
and the end-chemistry at the site of cleavage is homo-
geneous (i.e., one oligomer produced by cutting corre-
sponds to one nucleotide position on the polymer).
Footprinting experiments with paromomycin were car-
ried out in a total volume of 10 mL in the buffer, 10 mM
Tris HCl (pH 7), at room temperature (20 C). Under
these conditions, the RNA is in the monomeric form.
The protocol was to mix radiolabeled RNA (100,000
cpm) with unlabeled RNA, and to add increasing
amounts of paromomycin to successive samples in a
total volume of 9 mL. After mixing with a pipette, each
3670 M. P. McPike et al. / Bioorg. Med. Chem. 10 (2002) 3663–3672
solution was allowed to stand for 30 min. Then RNase I
or RNase T1 in a volume of 1mL was added and the
sample briefly mixed. The final concentrations of
labeled RNA and unlabeled RNA in the final reaction
volume of 10 mL were 0.05 and 1.1 mM, respectively.
For the RNase I experiments, the final drug con-
centrations were: 0, 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20,
25, 30, 35, 40, 45, and 50 mM. For the RNase T1
experiments, they were: 0, 10, 15, 20, 25, 30, 35, 40, 45,
55, and 60 mM.
Cutting was allowed to proceed for 1.5 min (RNase I)
or 10 min (RNase T1) and the cleavage reactions were
stopped by addition of 5 mL formamide loading buffer.
Before loading in the gel, samples were heated at 95 C
for 5 min and then immediately placed on ice. Eleven
mL of each sample was loaded into an 9% denaturing
PAGE gel, which ran at 800 V for 8 h at room tem-
perature. The cutting pattern was visualized with auto-
radiography (Figs 2 and 3) and the data were scanned
using the earlier described procedures.24 The spot
intensities in the control lanes show that a small amount
of the end-labeled c-RNA was fragmented prior to
addition of the cleavage agent; sites having a significant
amount of cutting in the control were not used in the
quantitative analysis. For sites showing binding, band
intensity for the fully occupied site was taken as the
average of the intensity at high drug concentration.
The corrected spot intensities are used to construct
footprinting plots, some of which are shown in Figs 4
and 5.
Circular dichroism
Circular dichroism titrations were carried out at 21 C
using an Aviv model 202 CD instrument. Scans of
wavelength were from 300 to 200 nm with a resolution
of 1 nm and data sampling every 2 nm. The starting
volume in the 1 cm path length cell was 350 mL with the
concentration of RNA being 0.5 mM in the buffer, 10
mM Tris–HCl (pH 7.0). Control experiments, in which
spectra were collected at various times after addition of
paromomycin to RNA and mixing, showed that binding
equilibrium was reached within the time of mixing and
collecting the data.
Spectra were collected immediately after addition of a
small volume of a solution of paromomycin (in the
above buffer) to a buffered solution of the RNA. After
subtracting the spectrum of the buffer blank, the spectra
were corrected for dilution (correction less than 10% at
the end of the titration) and e per nucleotide was cal-
culated. The formula used was e= /[(32.98)(171)‘c],
where e is in M1 cm1, c is the measured ellipticity in
degrees, l is the path length in cm, and c is the con-
centration of RNA, 0.5 mM. The paromomycin con-
centrations used in the titration were: 0, 0.28, 0.56,
0.76, 1.03, 1.40, 2.78, 5.54, 8.28, 11.0, 13.7, 16.4,
19.1, 23.1, 28.6, 33.6, 40.1, and 53.0 m. Results for
the first six concentrations were used to determine
the large binding constant. Paromomycin alone does
not exhibit a CD spectrum in the wavelength range
that was studied.
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